Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM42HXN)

• Drug Name: Atracurium Drug Info
• Synonyms: Atracurium Dibesylate; Tracrium (TN); 2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]; 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[1]

• Therapeutic Class: Neuromuscular Nondepolarizing Agents
• Cross-matching ID:
  PubChem CID: 47319
  ChEBI ID: CHEBI:2914
  CAS Number: CAS 64228-79-1
  TTD Drug ID: DM42HXN

Molecule-Related Drug Atlas

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[3]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[4]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[2]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[5]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[6]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[7]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[8]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[9]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[10]
TRIDMAC	DMWU41P	Mood disorder	6A60-6E23	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Antagonist	[2]

References

• [1] A preliminary assessment of atracurium, a new competitive neuromuscular blocking agent. Acta Anaesthesiol Scand. 1981 Feb;25(1):67-9.
• [2] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
• [3] Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
• [4] Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
• [5] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [8] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [9] Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
• [10] Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
• [11] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.